{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,11]],"date-time":"2025-07-11T10:43:12Z","timestamp":1752230592295,"version":"3.37.3"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2019,11,6]],"date-time":"2019-11-06T00:00:00Z","timestamp":1572998400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,11,6]],"date-time":"2019-11-06T00:00:00Z","timestamp":1572998400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100012553","name":"Chang Gung Memorial Hospital","doi-asserted-by":"crossref","award":["CMRPG8D0651"],"award-info":[{"award-number":["CMRPG8D0651"]}],"id":[{"id":"10.13039\/100012553","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1007\/s00198-019-05201-5","type":"journal-article","created":{"date-parts":[[2019,11,6]],"date-time":"2019-11-06T16:03:20Z","timestamp":1573056200000},"page":"475-483","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Underestimated fracture risk in postmenopausal women\u2014application of the hybrid intervention threshold"],"prefix":"10.1007","volume":"31","author":[{"given":"Y.","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8943-5056","authenticated-orcid":false,"given":"T.","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,11,6]]},"reference":[{"key":"5201_CR1","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1001\/jama.285.6.785","volume":"285","author":"NIH Consensus Development Panel","year":"2001","unstructured":"NIH Consensus Development Panel (2001) Osteoporosis prevention, diagnosis, and therapy. Jama 285:785\u2013795. \nhttps:\/\/doi.org\/10.1001\/jama.285.6.785","journal-title":"Jama"},{"key":"5201_CR2","doi-asserted-by":"publisher","first-page":"171","DOI":"10.5312\/wjo.v7.i3.171","volume":"7","author":"P Pisani","year":"2016","unstructured":"Pisani P, Renna MD, Conversano F, Casciaro E, Di Paola M, Quarta E, Muratore M, Casciaro S (2016) Major osteoporotic fragility fractures: risk factor updates and societal impact. World J Orthop 7:171\u2013181. \nhttps:\/\/doi.org\/10.5312\/wjo.v7.i3.171","journal-title":"World J Orthop"},{"key":"5201_CR3","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1001\/archinte.164.10.1108","volume":"164","author":"ES Siris","year":"2004","unstructured":"Siris ES, Chen YT, Abbott TA, Barrett-Connor E, Miller PD, Wehren LE, Berger ML (2004) Bone mineral density thresholds for pharmacological intervention to prevent fractures. Arch Intern Med 164:1108\u20131112. \nhttps:\/\/doi.org\/10.1001\/archinte.164.10.1108","journal-title":"Arch Intern Med"},{"key":"5201_CR4","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1007\/s11657-018-0510-0","volume":"13","author":"JA Kanis","year":"2018","unstructured":"Kanis JA, Johansson H, Harvey NC, McCloskey EV (2018) A brief history of FRAX. Arch Osteoporos 13:118. \nhttps:\/\/doi.org\/10.1007\/s11657-018-0510-0","journal-title":"Arch Osteoporos"},{"issue":"Suppl 2","key":"5201_CR5","doi-asserted-by":"publisher","first-page":"S407","DOI":"10.1007\/s00198-010-1253-y","volume":"21","author":"JA Kanis","year":"2010","unstructured":"Kanis JA, McCloskey EV, Johansson H, Oden A, Strom O, Borgstrom F (2010) Development and use of FRAX in osteoporosis. Osteoporos Int 21(Suppl 2):S407\u2013S413. \nhttps:\/\/doi.org\/10.1007\/s00198-010-1253-y","journal-title":"Osteoporos Int"},{"key":"5201_CR6","first-page":"283","volume":"20","author":"YC Lin","year":"2011","unstructured":"Lin YC, Pan WH (2011) Bone mineral density in adults in Taiwan: results of the Nutrition and Health Survey in Taiwan 2005-2008 (NAHSIT 2005-2008). Asia Pac J Clin Nutr 20:283\u2013291 \n1","journal-title":"Asia Pac J Clin Nutr"},{"key":"5201_CR7","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1007\/s11657-018-0467-z","volume":"13","author":"HH Lin","year":"2018","unstructured":"Lin HH, Huang CY, Hwang LC (2018) Association between metabolic syndrome and osteoporosis in Taiwanese middle-aged and elderly participants. Arch Osteoporos 13:48. \nhttps:\/\/doi.org\/10.1007\/s11657-018-0467-z","journal-title":"Arch Osteoporos"},{"key":"5201_CR8","unstructured":"Drug payment criteria. Chapter 5. Hormones & drugs affecting hormonal mechanism. Section 5.6 Anti-osteoporotic medications. National Health Insurance Administration Ministry of Health and Welfare. \nhttps:\/\/www.nhi.gov.tw\/Content_List.aspx?n=E70D4F1BD029DC37&topn=3FC7D09599D25979\n\n. Assessed 17 April 2019"},{"key":"5201_CR9","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s11657-016-0278-z","volume":"11","author":"JA Kanis","year":"2016","unstructured":"Kanis JA, Harvey NC, Cooper C, Johansson H, Oden A, McCloskey EV (2016) A systematic review of intervention thresholds based on FRAX: a report prepared for the National Osteoporosis Guideline Group and the International Osteoporosis Foundation. Arch Osteoporos 11:25. \nhttps:\/\/doi.org\/10.1007\/s11657-016-0278-z","journal-title":"Arch Osteoporos"},{"key":"5201_CR10","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.bone.2016.12.016","volume":"104","author":"HP Dimai","year":"2017","unstructured":"Dimai HP (2017) Use of dual-energy X-ray absorptiometry (DXA) for diagnosis and fracture risk assessment; WHO-criteria, T- and Z-score, and reference databases. Bone 104:39\u201343. \nhttps:\/\/doi.org\/10.1016\/j.bone.2016.12.016","journal-title":"Bone"},{"key":"5201_CR11","unstructured":"WHO scientific group on the assessment of osteoporosis at primary health care level \nhttps:\/\/www.who.int\/chp\/topics\/Osteoporosis.pdf\n\n. Assessed 17 April 2019"},{"key":"5201_CR12","unstructured":"FRAX (Fracture Risk Assessment Tool): Taiwan. \nhttps:\/\/www.sheffield.ac.uk\/FRAX\/tool.aspx?country=26\n\n. Assessed 17 April 2019"},{"key":"5201_CR13","doi-asserted-by":"publisher","first-page":"2359","DOI":"10.1007\/s00198-014-2794-2","volume":"25","author":"F Cosman","year":"2014","unstructured":"Cosman F, de Beur SJ, LeBoff MS, Lewiecki EM, Tanner B, Randall S, Lindsay R (2014) Clinician\u2018s guide to prevention and treatment of osteoporosis. Osteoporos Int 25:2359\u20132381. \nhttps:\/\/doi.org\/10.1007\/s00198-014-2794-2","journal-title":"Osteoporos Int"},{"key":"5201_CR14","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1007\/s00774-013-0495-0","volume":"32","author":"JS Hwang","year":"2014","unstructured":"Hwang JS, Chan DC, Chen JF, Cheng TT, Wu CH, Soong YK, Tsai KS, Yang RS (2014) Clinical practice guidelines for the prevention and treatment of osteoporosis in Taiwan: summary. J Bone Miner Metab 32:10\u201316. \nhttps:\/\/doi.org\/10.1007\/s00774-013-0495-0","journal-title":"J Bone Miner Metab"},{"key":"5201_CR15","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1002\/jbmr.2531","volume":"30","author":"JA Kanis","year":"2015","unstructured":"Kanis JA, McCloskey EV, Harvey NC, Johansson H, Leslie WD (2015) Intervention thresholds and the diagnosis of osteoporosis. J Bone Miner Res 30:1747\u20131753. \nhttps:\/\/doi.org\/10.1002\/jbmr.2531","journal-title":"J Bone Miner Res"},{"key":"5201_CR16","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1007\/s00774-012-0371-3","volume":"30","author":"JA Kanis","year":"2012","unstructured":"Kanis JA, Johansson H, Oden A, McCloskey EV (2012) The distribution of FRAX((R))-based probabilities in women from Japan. J Bone Miner Metab 30:700\u2013705. \nhttps:\/\/doi.org\/10.1007\/s00774-012-0371-3","journal-title":"J Bone Miner Metab"},{"key":"5201_CR17","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1007\/s00198-015-3176-0","volume":"26","author":"E McCloskey","year":"2015","unstructured":"McCloskey E, Kanis JA, Johansson H, Harvey N, Oden A, Cooper A, Cooper C, Francis RM, Reid DM, Marsh D, Selby P, Thompson F, Hewitt S, Compston J (2015) FRAX-based assessment and intervention thresholds--an exploration of thresholds in women aged 50 years and older in the UK. Osteoporos Int 26:2091\u20132099. \nhttps:\/\/doi.org\/10.1007\/s00198-015-3176-0","journal-title":"Osteoporos Int"},{"key":"5201_CR18","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s11657-012-0109-9","volume":"7","author":"H Orimo","year":"2012","unstructured":"Orimo H, Nakamura T, Hosoi T, Iki M, Uenishi K, Endo N, Ohta H, Shiraki M, Sugimoto T, Suzuki T, Soen S, Nishizawa Y, Hagino H, Fukunaga M, Fujiwara S (2012) Japanese 2011 guidelines for prevention and treatment of osteoporosis--executive summary. Arch Osteoporos 7:3\u201320. \nhttps:\/\/doi.org\/10.1007\/s11657-012-0109-9","journal-title":"Arch Osteoporos"},{"key":"5201_CR19","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1007\/s00198-008-0712-1","volume":"19","author":"JA Kanis","year":"2008","unstructured":"Kanis JA, McCloskey EV, Johansson H, Strom O, Borgstrom F, Oden A (2008) Case finding for the management of osteoporosis with FRAX--assessment and intervention thresholds for the UK. Osteoporos Int 19:1395\u20131408. \nhttps:\/\/doi.org\/10.1007\/s00198-008-0712-1","journal-title":"Osteoporos Int"},{"key":"5201_CR20","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.bone.2014.09.015","volume":"69","author":"JS Chen","year":"2014","unstructured":"Chen JS, Simpson JM, Blyth FM, March LM (2014) Managing osteoporosis with FRAX(R) in Australia: proposed new treatment thresholds from the 45&Up Study cohort. Bone 69:148\u2013153. \nhttps:\/\/doi.org\/10.1016\/j.bone.2014.09.015","journal-title":"Bone"},{"key":"5201_CR21","doi-asserted-by":"publisher","first-page":"3099","DOI":"10.1007\/s00198-017-4160-7","volume":"28","author":"H Johansson","year":"2017","unstructured":"Johansson H, Azizieh F, Al Ali N, Alessa T, Harvey NC, McCloskey E, Kanis JA (2017) FRAX- vs. T-score-based intervention thresholds for osteoporosis. Osteoporos Int 28:3099\u20133105. \nhttps:\/\/doi.org\/10.1007\/s00198-017-4160-7","journal-title":"Osteoporos Int"},{"key":"5201_CR22","doi-asserted-by":"publisher","first-page":"2257","DOI":"10.1007\/s00198-012-1958-1","volume":"23","author":"S Lekamwasam","year":"2012","unstructured":"Lekamwasam S, Adachi JD, Agnusdei D, Bilezikian J, Boonen S, Borgstrom F, Cooper C, Diez Perez A, Eastell R, Hofbauer LC, Kanis JA, Langdahl BL, Lesnyak O, Lorenc R, McCloskey E, Messina OD, Napoli N, Obermayer-Pietsch B, Ralston SH, Sambrook PN, Silverman S, Sosa M, Stepan J, Suppan G, Wahl DA, Compston JE (2012) A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis. Osteoporos Int 23:2257\u20132276. \nhttps:\/\/doi.org\/10.1007\/s00198-012-1958-1","journal-title":"Osteoporos Int"},{"key":"5201_CR23","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1056\/NEJMoa067312","volume":"356","author":"DM Black","year":"2007","unstructured":"Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, Cosman F, Lakatos P, Leung PC, Man Z, Mautalen C, Mesenbrink P, Hu H, Caminis J, Tong K, Rosario-Jansen T, Krasnow J, Hue TF, Sellmeyer D, Eriksen EF, Cummings SR (2007) Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356:1809\u20131822. \nhttps:\/\/doi.org\/10.1056\/NEJMoa067312","journal-title":"N Engl J Med"},{"key":"5201_CR24","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1056\/NEJMoa0809493","volume":"361","author":"SR Cummings","year":"2009","unstructured":"Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, Delmas P, Zoog HB, Austin M, Wang A, Kutilek S, Adami S, Zanchetta J, Libanati C, Siddhanti S, Christiansen C (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361:756\u2013765. \nhttps:\/\/doi.org\/10.1056\/NEJMoa0809493","journal-title":"N Engl J Med"},{"key":"5201_CR25","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1056\/nejm199511303332201","volume":"333","author":"UA Liberman","year":"1995","unstructured":"Liberman UA, Weiss SR, Broll J, Minne HW, Quan H, Bell NH, Rodriguez-Portales J, Downs RW Jr, Dequeker J, Favus M (1995) Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med 333:1437\u20131443. \nhttps:\/\/doi.org\/10.1056\/nejm199511303332201","journal-title":"N Engl J Med"},{"key":"5201_CR26","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1056\/nejm200105103441904","volume":"344","author":"RM Neer","year":"2001","unstructured":"Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH (2001) Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344:1434\u20131441. \nhttps:\/\/doi.org\/10.1056\/nejm200105103441904","journal-title":"N Engl J Med"},{"key":"5201_CR27","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1016\/j.bone.2009.02.014","volume":"44","author":"JA Kanis","year":"2009","unstructured":"Kanis JA, Johansson H, Oden A, McCloskey EV (2009) Bazedoxifene reduces vertebral and clinical fractures in postmenopausal women at high risk assessed with FRAX. Bone 44:1049\u20131054. \nhttps:\/\/doi.org\/10.1016\/j.bone.2009.02.014","journal-title":"Bone"},{"key":"5201_CR28","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1002\/jbmr.1606","volume":"27","author":"EV McCloskey","year":"2012","unstructured":"McCloskey EV, Johansson H, Oden A, Austin M, Siris E, Wang A, Lewiecki EM, Lorenc R, Libanati C, Kanis JA (2012) Denosumab reduces the risk of osteoporotic fractures in postmenopausal women, particularly in those with moderate to high fracture risk as assessed with FRAX. J Bone Miner Res 27:1480\u20131486. \nhttps:\/\/doi.org\/10.1002\/jbmr.1606","journal-title":"J Bone Miner Res"},{"key":"5201_CR29","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1007\/s00198-008-0786-9","volume":"20","author":"EV McCloskey","year":"2009","unstructured":"McCloskey EV, Johansson H, Oden A, Vasireddy S, Kayan K, Pande K, Jalava T, Kanis JA (2009) Ten-year fracture probability identifies women who will benefit from clodronate therapy--additional results from a double-blind, placebo-controlled randomised study. Osteoporos Int 20:811\u2013817. \nhttps:\/\/doi.org\/10.1007\/s00198-008-0786-9","journal-title":"Osteoporos Int"},{"key":"5201_CR30","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1359\/jbmr.061008","volume":"22","author":"EV McCloskey","year":"2007","unstructured":"McCloskey EV, Beneton M, Charlesworth D, Kayan K, deTakats D, Dey A, Orgee J, Ashford R, Forster M, Cliffe J, Kersh L, Brazier J, Nichol J, Aropuu S, Jalava T, Kanis JA (2007) Clodronate reduces the incidence of fractures in community-dwelling elderly women unselected for osteoporosis: results of a double-blind, placebo-controlled randomized study. J Bone Miner Res 22:135\u2013141. \nhttps:\/\/doi.org\/10.1359\/jbmr.061008","journal-title":"J Bone Miner Res"},{"key":"5201_CR31","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.1056\/NEJMoa1808082","volume":"379","author":"IR Reid","year":"2018","unstructured":"Reid IR, Horne AM, Mihov B, Stewart A, Garratt E, Wong S, Wiessing KR, Bolland MJ, Bastin S, Gamble GD (2018) Fracture prevention with zoledronate in older women with osteopenia. N Engl J Med 379:2407\u20132416. \nhttps:\/\/doi.org\/10.1056\/NEJMoa1808082","journal-title":"N Engl J Med"},{"key":"5201_CR32","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/s0140-6736(17)32640-5","volume":"391","author":"L Shepstone","year":"2018","unstructured":"Shepstone L, Lenaghan E, Cooper C, Clarke S, Fong-Soe-Khioe R, Fordham R, Gittoes N, Harvey I, Harvey N, Heawood A, Holland R, Howe A, Kanis J, Marshall T, O'Neill T, Peters T, Redmond N, Torgerson D, Turner D, McCloskey E (2018) Screening in the community to reduce fractures in older women (SCOOP): a randomised controlled trial. Lancet 391:741\u2013747. \nhttps:\/\/doi.org\/10.1016\/s0140-6736(17)32640-5","journal-title":"Lancet"},{"key":"5201_CR33","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1007\/s10900-014-9853-7","volume":"39","author":"RA Begum","year":"2014","unstructured":"Begum RA, Ali L, Akter J, Takahashi O, Fukui T, Rahman M (2014) Osteopenia and osteoporosis among 16-65 year old women attending outpatient clinics. J Community Health 39:1071\u20131076. \nhttps:\/\/doi.org\/10.1007\/s10900-014-9853-7","journal-title":"J Community Health"},{"key":"5201_CR34","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1007\/s11657-013-0136-1","volume":"8","author":"E Hernlund","year":"2013","unstructured":"Hernlund E, Svedbom A, Ivergard M, Compston J, Cooper C, Stenmark J, McCloskey EV, Jonsson B, Kanis JA (2013) Osteoporosis in the European Union: medical management, epidemiology and economic burden. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Arch Osteoporos 8:136. \nhttps:\/\/doi.org\/10.1007\/s11657-013-0136-1","journal-title":"Arch Osteoporos"},{"key":"5201_CR35","doi-asserted-by":"publisher","first-page":"180","DOI":"10.3803\/EnM.2013.28.3.180","volume":"28","author":"J Lee","year":"2013","unstructured":"Lee J, Lee S, Jang S, Ryu OH (2013) Age-related changes in the prevalence of osteoporosis according to gender and skeletal site: the Korea National Health and Nutrition Examination Survey 2008-2010. Endocrinol Metab (Seoul) 28:180\u2013191. \nhttps:\/\/doi.org\/10.3803\/EnM.2013.28.3.180","journal-title":"Endocrinol Metab (Seoul)"},{"key":"5201_CR36","doi-asserted-by":"publisher","first-page":"25206","DOI":"10.1038\/srep25206","volume":"6","author":"YC Lu","year":"2016","unstructured":"Lu YC, Lin YC, Lin YK, Liu YJ, Chang KH, Chieng PU, Chan WP (2016) Prevalence of osteoporosis and low bone mass in older Chinese population based on bone mineral density at multiple skeletal sites. Sci Rep 6:25206. \nhttps:\/\/doi.org\/10.1038\/srep25206","journal-title":"Sci Rep"},{"key":"5201_CR37","doi-asserted-by":"publisher","first-page":"2520","DOI":"10.1002\/jbmr.2269","volume":"29","author":"NC Wright","year":"2014","unstructured":"Wright NC, Looker AC, Saag KG, Curtis JR, Delzell ES, Randall S, Dawson-Hughes B (2014) The recent prevalence of osteoporosis and low bone mass in the United States based on bone mineral density at the femoral neck or lumbar spine. J Bone Miner Res 29:2520\u20132526. \nhttps:\/\/doi.org\/10.1002\/jbmr.2269","journal-title":"J Bone Miner Res"},{"key":"5201_CR38","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s00198-018-4704-5","volume":"30","author":"JA Kanis","year":"2019","unstructured":"Kanis JA, Cooper C, Rizzoli R, Reginster JY (2019) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 30:3\u201344. \nhttps:\/\/doi.org\/10.1007\/s00198-018-4704-5","journal-title":"Osteoporos Int"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-019-05201-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00198-019-05201-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-019-05201-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,5]],"date-time":"2020-11-05T00:32:04Z","timestamp":1604536324000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00198-019-05201-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,6]]},"references-count":38,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["5201"],"URL":"https:\/\/doi.org\/10.1007\/s00198-019-05201-5","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"type":"print","value":"0937-941X"},{"type":"electronic","value":"1433-2965"}],"subject":[],"published":{"date-parts":[[2019,11,6]]},"assertion":[{"value":"25 April 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 November 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the local Institutional Review Board of Chang Gung Memorial Hospital (102-1878B). All participants provided written informed consent prior to participating in this program.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}